Please use this identifier to cite or link to this item:
http://repository.kln.ac.lk/handle/123456789/21274
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Niriella, M.A. | |
dc.contributor.author | Ediriweera, D.S. | |
dc.contributor.author | de Silva, A.P. | |
dc.contributor.author | Premaratna, R. | |
dc.contributor.author | Balasooriya, P. | |
dc.contributor.author | Duminda, K.D. | |
dc.contributor.author | Malavige, N.G. | |
dc.contributor.author | Wanigasuriya, K. | |
dc.contributor.author | Lekamwasam, S. | |
dc.contributor.author | Kularathne, S.A. | |
dc.contributor.author | Siribaddana, S. | |
dc.contributor.author | de Silva, H.J. | |
dc.contributor.author | Jayasinghe, S. | |
dc.date.accessioned | 2020-08-31T04:11:07Z | |
dc.date.available | 2020-08-31T04:11:07Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | Trials. 2020;21(1):748. | en_US |
dc.identifier.issn | 1745-6215 (Electronic) | |
dc.identifier.issn | 1745-6215 (Linking) | |
dc.identifier.uri | http://repository.kln.ac.lk/handle/123456789/21274 | |
dc.description | Indexed in MEDLINE, Scopus, SCIE | en_US |
dc.description.abstract | BACKGROUND: The first case of a coronavirus 2019 (COVID-19) infection in a Sri Lankan was reported on March 11, 2020. The situation in Sri Lanka changed with the rapid increase of personnel contracting COVID-19 in a naval base camp that housed more than 4000 people. This provided a unique opportunity to study the effectiveness of hydroxychloroquine (HCQ) for post-exposure prophylaxis (PEP), while taking stringent, non-pharmacologic, public health measures to prevent spread. Our aim is to study the effectiveness and safety of HCQ for PEP among naval personnel with exposure to COVID-19-positive patients. METHODS/DESIGN: This is a placebo-controlled, randomized, clinical trial carried out in the naval base camp and quarantine centers of the Sri Lanka Navy, Ministry of Defense, Sri Lanka. Navy personnel who are exposed to a patient with confirmed COVID-19 infection but test negative for the virus on reverse real-time polymerase chain reaction (rRT-PCR) at recruitment will be randomized, 200 to each arm, to receive HCQ or placebo and monitored for the development of symptoms or rRT-PCR positivity for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus for 14 days. DISCUSSION: This trial will provide high-quality evidence of the effectiveness and safety of HCQ as PEP for COVID-19. The study design is unique due to the circumstances of the outbreak in a confined area among otherwise healthy adults, at a relatively early stage of its spread. TRIAL REGISTRATION: Sri Lanka Clinical Trials Registry (SLCTR) SLCTR/2020/011. Registered on 04 May 2020. KEYWORDS: COVID-19; HCQ; Hydroxychloroquine; Post-exposure; Prophylaxis; Randomized controlled trial; SARS-CoV-2; Sri Lanka. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | BioMed Central | en_US |
dc.subject | Clinical Protocols | en_US |
dc.subject | Randomized Controlled Trial | en |
dc.title | Hydroxychloroquine for post-exposure prophylaxis of COVID-19 among naval personnel in Sri Lanka: study protocol for a randomized, controlled trial | en_US |
dc.type | Article | en_US |
Appears in Collections: | Journal/Magazine Articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Hydroxychloroquine for post-exposure.pdf | 381.48 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.